Aspirin and clopidogrel together reduce the risk of recurrent thrombosis-related events in patients with acute coronary syndromes or stent revascularization and may reduce thrombosis-induced saphenous vein graft failure. In this retrospective, observational study, 4297 patients were assigned to 2 groups after coronary artery bypass graft surgery, based on medications prescribed at hospital discharge: aspirin only (n ¼ 3318) or aspirin plus clopidogrel (n ¼ 979). At 4-year followup, unadjusted survival was similar between the 2 groups (aspirin-clopidogrel, 87.9% vs aspirin-only, 88.8%, P ¼ .43). After statistical adjustment using Cox regression analysis, dual anti-platelet therapy at hospital discharge was not associated with improved survival (odds ratio 1.055, 95% confidence interval 0.7-1.4, P ¼ .72). In propensity score-based, casematched populations (962 patients each), similar results were obtained (odds ratio 0.996, 95% confidence interval 0.7-1.4, P ¼ .98). In our study population, aspirin plus clopidogrel did not provide survival benefit over treatment with aspirin alone in 4 years after coronary artery bypass graft surgery.
Introduction
Coronary artery bypass graft (CABG) surgery improves long-term survival in patients with leftmain or multivessel coronary artery disease and poor left ventricular function. 1 In early studies, saphenous vein grafts (SVGs), which have only a 50% patency rate after 15 years, were used in CABG surgery. 2 Long-term efficacy of CABG surgery has been improved by the use of internal mammary grafts, particularly the left internal mammary artery. Nevertheless, SVGs are often used, and graft failure, frequent and problematic, may occur early (1-30 days) due to perioperative thrombosis, within the first year after surgery due to aggressive intimal hyperplasia, or later due to aggressive atherosclerosis. The common mechanism at each time period for graft failure is thrombosis.
Aspirin is routinely used after CABG surgery to reduce the risk of SVG failure. The Post Coronary Artery Bypass Graft (Post-CABG) Trial demonstrated that adding low-dose anticoagulation with warfarin to aspirin therapy provided additional benefit, but only after a long period of follow-up. 3, 4 In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, patients with acute coronary syndromes treated with the combination of aspirin and clopidogrel had a lower risk of the combined end point-cardiovascular death, myocardial infarction, and stroke-than did patients treated with aspirin alone. 5 The greatest benefits of dual antiplatelet therapy were seen in patients with prior revascularization, particularly CABG surgery. This finding suggests that combination therapy may have a beneficial effect on SVG patency, thereby improving survival in CABG patients. We have tested that hypothesis in an unselected population of patients referred for CABG surgery.
Patients and Methods

Patient Population
We used the Texas Heart Institute (THI) Research Database (THIRDBase) to identify Texas residents surviving to hospital discharge after their first coronary revascularization with CABG surgery (n ¼ 4297) between January 2000 and December 2005. Patients were classified into 2 groups based on their discharge prescription: aspirin alone (n ¼ 3318) or aspirin plus clopidogrel (n ¼ 979). We obtained vital statistics on these patients from the US Department of Vital Statistics database.
Demographic variables and in-hospital outcome were obtained from the THIRDBase. Urgent CABG surgery was defined as CABG performed within 48 hours of admission to the hospital. Advanced age was defined as age 65 years, and obesity as a body mass index of 25. We used the Kaplan-Meier method to estimate 4-year survival rates. Cox proportional hazards modeling was used to adjust for differences in baseline characteristics and to identify significant predictors of long-term mortality. For a separate method of comparison, we created 2 propensitymatched groups of 962 patients each (total n ¼ 1924). In these groups, the impact of combination antiplatelet therapy was reexamined using 4-year survival curves as estimated by Kaplan-Meier analysis and log-rank statistic.
Statistical Analysis
Patient characteristics and event rates were recorded as binary categorical variables and reported as percentages. We used Pearson's chi-square test to analyze discrete variables, and Student t test to analyze continuous variables. P values less than 0.05 were considered significant. SAS 9.1 software (SAS Institute, Cary, NC) for the Windows operating system was used for analysis. We developed logistic regression and Cox proportional hazard models that used a forward stepwise variable selection process to determine which clinical variables affected early and late mortality. Propensity scores were computed based on significant predictors of logistic regression using grouping variable as binary outcome.
For the case-matched study population, pairs of patients with similar propensity scores were selected from the 2 groups and used in subsequent analysis. To express survival differences in percentages, we constructed Kaplan-Meier survival curves for the aspirin and the aspirin plus clopidogrel groups.
Results
Our study population comprised 4297 patients who underwent their first CABG surgery during the study period. Most patients were treated with aspirin alone (n ¼ 3318), and 979 patients were treated with aspirin and clopidogrel. The median follow-up time was 737 days (range, 2-4264 days).
Patient Demographics
Baseline demographic variables are shown in Table 1 . The combination therapy group had a higher prevalence of diabetes, hypertension, hyperlipidemia, peripheral vascular disease, cerebrovascular disease, and transient ischemic attacks than did the aspirin-only group. However, patients with New York Heart Association (NYHA) functional class 3 or 4 heart failure or with a history of valvular heart disease were more prevalent in the aspirin-only group than in the combination group.
Outcomes in the Unmatched Population
The 30-day mortality was 0.18% in the aspirin group and 0.10% in the combination therapy group (P ¼ .59). Univariate and multivariate predictors of long-term mortality (beyond 30 days after discharge) are shown in Table 2 . The most important predictors were age greater than 65 years and a history of congestive heart failure. Antiplatelet therapy prescribed at hospital discharge had no apparent effect on longterm mortality. Kaplan-Meier-estimated 4-year survival was 88.8% in the aspirin-only group and 87.9% in the combination therapy group (P ¼ .43, hazard ratio [HR] 1.055, 95% confidence interval [CI] 0.7-1.4; Figure 1 ).
Outcome in the Matched Groups
We matched 962 patients from each of the 2 treatment groups according to their demographic and clinical characteristics. The 30-day mortality was 0.21% in the aspirin group and 0.10% in the combination therapy group (P ¼ .56). The 4-year survival rate, as estimated by Kaplan-Meier analysis, was 87.1% in the aspirin group and 87.8% in the combination therapy group (P ¼ .74, HR 0.996, 95% CI 0.7-1.4; Figure 2 ). No statistically significant difference was found in the baseline clinical characteristics of the case-matched groups ( Table 3 ). Predictors of mortality in the matched population derived by Cox regression analysis are shown in Table 4 . The effect of combination therapy was not significant (HR 0.996, 95% CI 0.7-1.4). 
Discussion
In this nonrandomized, retrospective analysis of patients undergoing CABG surgery, we found that the use of combination antiplatelet therapy (aspirin plus clopidogrel) did not improve survival over therapy with aspirin alone in the first 4 years after surgery in patients with all clinical presentations. We found similar results in the propensity-matched populations. An estimated 467 000 CABG surgeries were performed in the United States in 2003. 6 Surgeons use several vascular conduits, such as saphenous veins, radial arteries, and internal mammary arteries, with respective graft patency rates of 86.4%, 91.8%, and 91%, at the end of 1 year. 2, 7 Although a popular choice, SVGs have a 6-month occlusion rate of 12.2% 8 and an annual occlusion rate of 1% to 2% from 1 to 6 years after surgery, and 4% to 5%, thereafter. By 15 years after CABG surgery, one half of all SVGs are expected to be occluded. 2, [9] [10] [11] Graft patency has an important effect on long-term survival, as established by the large body of literature showing the positive impact of the use of the internal mammary artery as a graft to the left anterior descending coronary artery.
A long-term follow-up of the Post-CABG trial suggested that low-dose anticoagulation reduced the progression of atherosclerosis. 4 Furthermore, CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events), CURE, and CREDO (Clopidogrel for the Reduction of Events During Observation) trials indicated that potent antiplatelet therapy may be of even greater value. 5, 12, 13 Our results, however, failed to prove that combination antiplatelet therapy was superior to aspirin alone in providing survival benefit in the first 4 years after CABG surgery.
Limitations
Our study was a single-center, observational study with an end point of survival only and no measure of long-term drug therapy compliance. Thus, dual antiplatelet therapy may possibly have had an effect that we were unable to show due to early drug cessation and our inability to reliably measure the incidence of reinfarction and repeat revascularization. Because of our relatively small sample size, Cox proportional hazards modeling and propensity score modeling may have failed to completely correct for differences in baseline patient variables in the 2 populations. The Post-CABG trial followed patients for a mean of 4.3 years and found that warfarin was no different than placebo in reducing the progression of atherosclerosis in CABGs. 3 However, longer follow-up revealed reductions in mortality in the warfarin arm compared with the placebo arm. 4 In our study, patients were followed for only 4 years, and the end points of myocardial infarction and repeat revascularization were not examined. Longer follow-up may be required to reveal the effect of dual antiplatelet therapy on the end point of survival, particularly given the impact of the use of the internal mammary artery in the grafting procedure. Abbreviations: CABG, coronary artery bypass grafting; CI, confidence interval.
Conclusions
Data from randomized trials have suggested that dual antiplatelet therapy, continued for at least 1 year, protects patients with acute coronary syndromes who are referred for CABG surgery from the combined end point of death, myocardial infarction, and repeat revascularization. In our nonrandomized, retrospective, observational database study, we found no difference in survival between patients prescribed aspirin alone and those prescribed aspirin plus clopidogrel in the first 4 years after routine CABG surgery. However, we did not study the use of dual antiplatelet therapy in preventing a combined end point of death, myocardial infarction, and repeat revascularization or for treatment beyond 4 years.
